Hurricanelover
Diamond Member
- Oct 4, 2021
- 3,557
- 4,145
- 1,938
Cancer Research in the US is World Class Because of its Broad Base of Funding − With the Government Pulling Out, Its Future is Uncertain
[/size] by Jeffrey MacKeigan, Ph.D.
April 28, 2025
Extract:
Cancer is close to the biggest killer of Americans yearly. Ending this disease would save hundreds of billions yearly. It is worth every penny and would greatly enhance quality of life not having to deal with it. It is the greatest enemy this society faces.
[/size] by Jeffrey MacKeigan, Ph.D.
April 28, 2025
Extract:
Read more here: https://theconversation.com/cancer-research-in-the-us-is-world-class-because-of-its-broad-base-of-funding-with-the-government-pulling-out-its-future-is-uncertain-254536(The Conversation) While private foundations are vital partners for cancer research, they cannot replace the scale and consistency of federal funding. Total U.S. philanthropic funding for cancer research is estimated at a few billion dollars per year, spread across hundreds of organizations. In comparison, the federal government has typically contributed roughly five to eight times more than philanthropy to cancer research each year.
Industry innovation − and its priorities
Private-sector innovation is essential for translating discoveries into treatments. In 2021, nearly 80% of the roughly $57 billion the U.S. spent on cancer drugs came from pharmaceutical and biotech companies. Many of the treatments used in oncology today, including immunotherapies and targeted therapies, emerged from collaborations between academic labs and industry partners.
But commercial priorities don’t always align with public health needs. Companies naturally focus on areas with strong financial returns: common cancers, projects that qualify for fast-track regulatory approval, and high-priced drugs. Rare cancers, pediatric cancers and basic science often receive less attention.
Industry is also saddled with uncertainty. Rising R&D costs, tough regulatory requirements and investor wariness have created a challenging environment to bring new drugs to market. Several biotech startups have folded or downsized in the past year, leaving promising new drugs stranded in limbo in the lab before they can reach clinical trials.
Without federal or philanthropic entities to pick up the slack, these discoveries may never reach the patients who need them.
Cancer is close to the biggest killer of Americans yearly. Ending this disease would save hundreds of billions yearly. It is worth every penny and would greatly enhance quality of life not having to deal with it. It is the greatest enemy this society faces.